



(12) Translation of
European patent specification

(11) NO/EP 3324977 B1

NORWAY	(19) NO	
	(51) Int Cl.	
	<i>C07D 243/16 (2006.01)</i>	<i>A61P 31/12 (2006.01)</i>
	<i>A61K 31/5513 (2006.01)</i>	<i>A61P 31/16 (2006.01)</i>
	<i>A61K 31/56 (2006.01)</i>	<i>C07D 413/12 (2006.01)</i>
	<i>A61K 31/58 (2006.01)</i>	<i>C07D 413/14 (2006.01)</i>
	<i>A61K 45/06 (2006.01)</i>	<i>C07D 417/14 (2006.01)</i>
	<i>A61P 11/00 (2006.01)</i>	

Norwegian Industrial Property Office


(45)	Translation Published	2022.11.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.07.13
(86)	European Application Nr.	16828528.6
(86)	European Filing Date	2016.07.21
(87)	The European Application's Publication Date	2018.05.30
(30)	Priority	2015.07.22, US, 201562195648 P 2016.05.12, US, 201662335227 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Enanta Pharmaceuticals, Inc., 500 Arsenal Street, Watertown, MA 02472, USA
(72)	Inventor	SHOOK, Brian, C., 199 Mohawk Path, Holliston, MA 01746, USA KIM, In, Jong, 20 Phinney Road, Lexington, MA 02421, USA BLAISDELL, Thomas, P., 153 Lake Shore Road Unit 2, Brighton, MA 02135, USA YU, Jianming, 100 Marion Drive, Plainsboro, NJ 08536, USA PANARESE, Joseph, 1 Stone Lane, Malden, MA 02148, USA OR, Yat, Sun, 169 Fayette Street, Watertown, MA 02472, USA
(74)	Agent or Attorney	Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark

(54)	Title	BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS
(56)	References Cited:	US-A1- 2007 142 403 US-A1- 2008 139 536 US-A1- 2010 015 063 WO-A1-2016/166546 US-A1- 2007 185 094 MICHAEL OFFEL ET AL: "Synthesis of Substituted 3-Anilino-5-phenyl-1,3-dihydro- 2H-1,4-benzodiazepine-2-ones and their Evaluation as Cholecystokinin-Ligands", ARCHIV DER PHARMAZIE, vol. 339, no. 4, 1 April 2006 (2006-04-01) , pages 163-173, XP055530910, Weinheim ISSN: 0365-6233, DOI: 10.1002/ardp.200500217

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse representert av formel (I):



eller et farmasøytisk akseptabelt salt derav, hvor:

R_1 velges fra gruppen som består av:

- 1) hydrogen;
- 2) halogen;
- 3) CN;
- 4) eventuelt substituert -C₁-C₈ alkyl; og
- 5) eventuelt substituert -C₁-C₈ alkyl -O-R₁₁;

R_2 og R_5 hver velges uavhengig fra gruppen som består av:

- 1) hydrogen; og
- 2) eventuelt substituert -C₁-C₈ alkyl;

A velges fra gruppen som består av:

- 1) eventuelt substituert heteroaryl
- 2) eventuelt substituert -C₃-C₁₂ sykloalkyl;
- 3) eventuelt substituert -C₃-C₁₂ sykloalkenyl
- 4) eventuelt substituert aryl;

R_3 er hydrogen eller R_{11} ;

R_4 velges fra gruppen som består av:

- 1) eventuelt substituert -C₃-C₁₂ sykloalkyl;
- 2) eventuelt substituert -C₃-C₁₂ sykloalkenyl;
- 3) eventuelt substituert 3- til 12-leddet heterosyklyl;
- 4) eventuelt substituert aryl;
- 5) eventuelt substituert heteroaryl;
- 6) eventuelt substituert aryl-O-;
- 7) eventuelt substituert heteroaryl-O;
- 8) eventuelt substituert aryl-C₁-C₄-alkyl; og
- 9) eventuelt substituert heteroaryl-C₁-C₄-alkyl;

hver R₆ er den samme eller forskjellig og uavhengig valgt fra hydrogen, halogen, hydroksyl, beskyttet hydroksyl, cyano, amino, beskyttet amino, nitro, eventuelt substituert -C₁-C₈ alkyl, eventuelt substituert -C₁-C₈ alkoksy, eventuelt substituert -NHC₁-C₈ alkyl, eventuelt substituert -S(-C₁-C₈ alkyl), eventuelt substituert -SO₂-(-C₁-C₈ alkyl), - eventuelt substituert -SO₂-NH-(-C₁-C₈ alkyl), eventuelt substituert -NH-SO₂-(-C₁-C₈ alkyl), -CO₂R₁₂ -NR₁₃R₁₄, og - CO-NR₁₃R₁₄;


R₁₁ og R₁₂ hver velges uavhengig fra gruppen som består av:

- 1) eventuelt substituert -C₁-C₈ alkyl;
- 2) eventuelt substituert -C₂-C₈ alkenyl;
- 3) eventuelt substituert -C₂-C₈ alkynyl;
- 4) eventuelt substituert -C₃-C₈ sykloalkyl;
- 5) eventuelt substituert -C₃-C₈ sykloalkenyl;
- 6) eventuelt substituert 3- til 8-leddet heterosykloalkyl;
- 7) eventuelt substituert aryl; og
- 8) eventuelt substituert heteroaryl;

R₁₃ og R₁₄ hver uavhengig velges fra hydrogen, eventuelt substituert -C₁-C₈-alkyl, eventuelt substituert -C₂-C₈-alkenyl, eventuelt substituert -C₂-C₈-alkynyl; eventuelt substituert -C₃-C₈-sykloalkyl, -C(O)R₁₂, -S(O)₂R₁₂ og -S(O)₂NHR₁₂, og





eventuelt substituert - C₁-C₈-alkoksy; alternativt, R₁₃ og R₁₄ tas sammen med nitrogenet de festet til for å danne en heterosyklig ring; og n er 0, 1, 2, 3 eller 4.

2. Forbindelsen ifølge krav 1, representert av formel (Ib),








eller et farmasøytsk akseptabelt salt derav.

3. Forbindelsen ifølge krav 1, hvori A velges fra ett av følgende ved fjerning av to hydrogenatomer:



hvor i hver av de vist ovenfor eventuelt substituert når det er mulig.

4. Forbindelsen ifølge krav 1, hvor R₄ velges fra ett av følgende ved fjerning av ett hydrogenatom:








hvor hvert av de vist ovenfor eventuelt substitueres når det er mulig.

5. Forbindelsen ifølge krav 1, hvori R₄ eventuelt substitueres med én, to eller tre av følgende substituenter:





halo, -CH₃, -CF₃, -OCF₃, -CN, -NH₂, -OH, -CH₂N(CH₃)₂, -C(O)CH₃, eventuelt substituert -NH-(C₁-C₆)alkyl, eventuelt substituert -NH-(C₁-C₆)alkyl-(C₁-C₆)alkoksy, eventuelt substituert -SO₂-(C₁-C₆)alkyl, eventuelt substituert -SO₂-NH-(C₁-C₆)alkyl, eventuelt substituert -NH-SO₂-(C₁-C₆)alkyl, eventuelt substituert 3- to 12-ledet heterosykloalkyl, eventuelt substituert aryl, eventuelt substituert heteroaryl,
eventuelt substituert -C₁-C₈-alkyl, eventuelt substituert -C₁-C₈-alkenyl, eventuelt substituert -C₃-C₈-sykloalkyl, eventuelt substituert -C₃-C₈-sykloalkenyl, og
eventuelt substituert -C₁-C₈-alkoksy.

6. Forbindelsen ifølge krav 1 hvor R₄ eventuelt substitueres av en eller to eller tre av følgende substituenter:

CH₃, CN, fluor, klor, CH₃O-, CH₃C(O)-, CH₃OCH₂-, CH₃OCH₂CH₂O-, -CF₃, CF₃O-,







7. Forbindelsen ifølge krav 1, representert ved formel (IIa-1), (IIa-2), (IIb-1) eller (IIb-2), eller et farmasøytisk akseptabelt salt derav,







hvor R₂, R₃, R₄, R₅, R₆, n og A er som definert i krav 1.

8. Forbindelsen ifølge krav 1, representert av formel (IV-1), (IV-2), (IV-3) eller (IV-4), eller et farmasøytisk akseptabelt salt derav,















hvor R₁, R₂, R₃, R₄, R₅, R₆ og n er som definert i krav 1.





9. Forbindelsen ifølge krav 1, representert av formel (V-1), (V-2), (V-3) eller (V-4),



eller et farmasøytisk akseptabelt salt derav, hvor R₁, R₂, R₃, R₄, R₅, R₆ og n er som definert i krav 1.

10. Forbindelsen ifølge krav 1, representert ved en av formlene (Vla-1) til (Vlb-8),







eller et farmasøytisk akseptabelt salt derav,


hvor i


R₄ og R₆ er som definert i krav 1.


11. Forbindelsen ifølge krav 10, hvor i R₄ velges fra gruppene angitt i tabellen nedenfor, som hver eventuelt substitueres:

























12. Forbindelse valgt fra forbindelsene fremsatt nedenfor eller et farmasøytisk akseptabelt salt derav:















Eksempel	Struktur	Eksempel	Struktur
1		2	
3		4	
5		6	
7a		7b	
8		9	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
10a		10b	
11		12	
13		14	
15		16	
17		19	
20		21	
22		23	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
24		25	
26		27	
28		29	
30		31	
32		33	
34		35	
36		37	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
38		39	
40		41	
42		43	
44		45	
46		47	
48		49	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
50		51	
52		53	
54		55	
56		57	
58		59	
60		61	
62		63	











<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
64		65	
66		67	
68		69	
70		71	
72		73	
74		75	
76		77	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
80		81	
82		83	
84		85	
86		87	
88		89	
90		91	
92		93	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
94		95	
96		97	
		107	
108		109	
110		111	
112		113	
114		115	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
116		117	
118		119	
120		121	
122		123	
124a		124b	
125a		125b	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
126a		126b	
127		128	
129		130	
131		132	
133		134	
135		136	











<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
137		138	
139		140	
141		142	
143		144	
145		146	
147		148	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
149		150	
151		152	
153		154	
155		156	
157		158	
159		160	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
161		162	
163		164	
165		166	
167		168	
169		170	
171		172	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
173		174	
175		176	
177		178	
179		180	
181		182	
183		184	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
185		186	
187			
195		196	
197		198	
199		200	
201		202	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
		204	
205		206	
207		208	
209		210	
211		212	
		214	
215		216	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
217		218	
219		220	
221		222	
223		224	
225		226	
227		228	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
229		230	
231		232	
233		234	
235		236	
237		238	
239		240	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
241		242	
243		244	
245		246	
247		248	
249		250	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
251		252	
253		254	
255		256	
257		258	
259		260	
261		262	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
263		264	
265		266	
267		268	
269		270	
271		272	
273		274	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
275		276	
277		278	
279		280	
281		282	
283		284	
285		286	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
287		288	
289		290	
291		292	
293		294	
295		296	
297		298	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
299		300	
301		302	
303		304	
305		306	
307		308	
309		310	











<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
311		312	
313		314	
315		316	
317		318	
319		320	
321		322	
323		324	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
325		326	
327		328	
329		330	
331		332	
333		334	
335		336	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
337		338	
339		340	
341		342	
343		344	
345		346	
347		348	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
349		350	
351		352	
353		354	
355a		355b	
356		357	
358		359	











<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
360		361	
362		363	
364		365	
366		367	
368		369	
370		371	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
372		373	
374		375	
376		377	
378		379	
380		381	
382		383	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
384		385	
386		387	
388		389	
390		391	
392		393	
394		395	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
396		397	
398		399	
400		401	
402		403	
404		405	











<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
406		407	
408		409	
410		411	
412		413	
414		415	
416		417	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
418		419	
420		421	
422		423	
424		425	
426		427	











<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
428		429	
430		431	
432		433	
434		435	
436		437	
438		439	











<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
440		441	
442		443	
444		445	
446		447	
448		449	













<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
450		451	
452		453	
454		455	
456		457	
458		459	
460		461	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
462		463	
464		465	
466		467	
468		469	
470		471	
472		473	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
474		475	
476		477	
478		479	
480		481	
482		483	


<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
484		485	
486		487	
488		489	
490		491	
492		493	
494		495	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
496		497	
498		499	
500		501	
502		503	
504		505	

<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
			
506		507	
508		509	
510		511	
512		513	
514		515	


<i>Eksempel</i>	<i>Struktur</i>	<i>Eksempel</i>	<i>Struktur</i>
516		517	
518			

13. Forbindelsen ifølge krav 12, som har strukturen




eller et farmasøytisk akseptabelt salt derav.

14. Forbindelsen ifølge krav 12, som har strukturen




eller et farmasøytisk akseptabelt salt derav.

15. Forbindelsen ifølge krav 12, som har strukturen




eller et farmasøytisk akseptabelt salt derav.

16. Forbindelsen ifølge krav 12, som har strukturen




eller et farmasøytisk akseptabelt salt derav.

17. Forbindelsen ifølge krav 12, som har strukturen




eller et farmasøytisk akseptabelt salt derav.

18. Forbindelsen ifølge krav 12, som har strukturen




eller et farmasøytisk akseptabelt salt derav.

19. Forbindelsen ifølge krav 12, som har strukturen




eller et farmasøytisk akseptabelt salt derav.

20. Forbindelsen ifølge krav 12, som har strukturen



eller et farmasøytisk akseptabelt salt derav.

21. Forbindelsen ifølge krav 12, som har strukturen



eller et farmasøytisk akseptabelt salt derav.

22. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1 til 21, eller et farmasøytisk akseptabelt salt derav, i kombinasjon med en farmasøytisk akseptabel bærer, fortynningsmiddel eller eksipient.

23. Forbindelsen ifølge hvilket som helst av kravene 1 til 21, for anvendelse ved behandling eller forebygging av en respiratorisk syncytial virusinfeksjon.